R2810-ONC-16XX: A Phase 1 Neoadjuvant Study of Stereotactic Body Radiation Therapy With Systemic REGN2810 and Intraprostatic Ipilimumab, Alone or in Combination, in Patients With Locally Advanced Prostate Cancer Prior to Radical Prostatectomy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Cemiplimab (Primary) ; Ipilimumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 07 Nov 2019 Planned End Date changed from 1 Apr 2020 to 4 Nov 2019.
- 07 Nov 2019 Planned primary completion date changed from 31 Dec 2019 to 4 Nov 2019.
- 07 Nov 2019 Planned initiation date changed from 1 Dec 2018 to 24 Dec 2018.